[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100432253":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":44,"centralContacts":49,"locations":56,"responsibleParty":100,"collaborators":103,"id":107,"slug":54,"hasResults":108,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":54,"eligibilityCriteria":112,"healthyVolunteers":108,"sex":113,"minAge":54,"maxAge":114,"enrollmentInfo":115,"targetDuration":54,"studyType":118,"phases":119,"briefSummary":121,"conditions":122,"keywords":54,"overallStatus":59,"whyStopped":54,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":133},{"fullName":5,"class":6},"Emory University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Diagnostic (sMRI)","EXPERIMENTAL","Patients undergo sMRI over less than 1 hour within 7 days prior to start of standard of care radiation therapy and at 10 weeks.",[13,14],"Procedure: Magnetic Resonance Spectroscopic Imaging","Device: Proton Therapy",{"label":16,"type":17,"description":18,"interventionNames":19},"Group 2","ACTIVE_COMPARATOR","Patients will undergo 3-4 sMRI scans at baseline prior to RT, 1 month, 4 months, and 7 months after RT, and\u002For at any time of suspected tumor recurrence.",[13,14],[21,34],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"PROCEDURE","Magnetic Resonance Spectroscopic Imaging","Undergo sMRI",[9,16],[27,28,29,30,31,32,33],"1H- Nuclear Magnetic Resonance Spectroscopic Imaging","1H-nuclear magnetic resonance spectroscopic imaging","Magnetic Resonance Spectroscopy","MRS","MRS Imaging","MRSI","Proton Magnetic Resonance Spectroscopic Imaging",{"type":35,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"DEVICE","Proton Therapy","Target volume treatment",[9,16],[40,41,42,29,43],"Spectroscopic MRI","Proton Radiation Therapy","sMRI imaging","3D whole brain MR spectroscopic imaging sequence",[45],{"name":46,"affiliation":47,"role":48},"Bree R Eaton, MD","Emory University Hospital\u002FWinship Cancer Institute","PRINCIPAL_INVESTIGATOR",[50],{"name":51,"role":52,"phone":53,"phoneExt":54,"email":55},"Bree Eaton, MD","CONTACT","404-778-3473",null,"brupper@emory.edu",[57,77,91],{"facility":58,"status":59,"city":60,"state":61,"zip":62,"country":63,"cosmosGeoPoint":64,"geoPoint":69,"contacts":70},"Emory Proton Therapy Center","RECRUITING","Atlanta","Georgia","30308","United States",{"type":65,"coordinates":66},"Point",[67,68],-84.38798,33.749,{"lat":68,"lon":67},[71,75],{"name":72,"role":52,"phone":73,"phoneExt":54,"email":74},"Ardith R. DeShay","404-251-0753","adeshay@emory.edu",{"name":76,"role":48,"phone":54,"phoneExt":54,"email":54},"Bree R. Eaton, MD",{"facility":78,"status":79,"city":60,"state":61,"zip":80,"country":63,"cosmosGeoPoint":81,"geoPoint":83,"contacts":84},"Children's Healthcare of Atlanta - Scottish Rite","NOT_YET_RECRUITING","30322",{"type":65,"coordinates":82},[67,68],{"lat":68,"lon":67},[85,89],{"name":86,"role":52,"phone":87,"phoneExt":54,"email":88},"Christina Lomba","404-785-4803","christina.lomba@choa.org",{"name":90,"role":48,"phone":54,"phoneExt":54,"email":54},"Bree R. Eaton",{"facility":47,"status":59,"city":60,"state":61,"zip":80,"country":63,"cosmosGeoPoint":92,"geoPoint":94,"contacts":95},{"type":65,"coordinates":93},[67,68],{"lat":68,"lon":67},[96,99],{"name":97,"role":52,"phone":54,"phoneExt":54,"email":98},"Hillary Gaines","hillary.gaines@emoryhealthcare.org",{"name":76,"role":48,"phone":54,"phoneExt":54,"email":54},{"type":48,"investigatorFullName":101,"investigatorTitle":102,"investigatorAffiliation":5,"oldNameTitle":54,"oldOrganization":54},"Bree Eaton","Principal Investigator",[104],{"name":105,"class":106},"National Cancer Institute (NCI)","NIH","100432253",false,"NCT04908709","Spectroscopic MRI Guided Proton Therapy in Assessing Metabolic Change in Pediatric Patients With Brain Tumors","Spectroscopic MRI Guided Proton Therapy for Pediatric High-Grade Glioma (RAD4500)","Inclusion Criteria:\n\n* Pathologically diagnosed high-grade glioma (World Health Organization \\[WHO\\] grade 3-4). Patients with a radiographically diagnosed high-grade glioma may enroll prior to pathologic confirmation, but would be removed from study if pathology did not confirm the diagnosis of high-grade glioma.\n* Primary tumor located within the supratentorial brain.\n* Recommended to receive definitive radiation therapy.\n* Able to receive MRI scans.\n* Both males and females, and members of all races and ethnic groups are eligible for this trial.\n\nExclusion Criteria:\n\n* Patients with pacemakers, non-titanium aneurysm clips, neurostimulators, cochlear implants, non-titanium metal in ocular structures, or other incompatible implants which makes MRI safety an issue are excluded.\n* Patients that have any significant medical illnesses that in the investigator's opinion cannot be adequately tolerate MRI scan are excluded.\n* Pathology demonstrated low-grade glioma or other benign or non-invasive brain tumor.","ALL","21 Years",{"count":116,"type":117},25,"ESTIMATED","INTERVENTIONAL",[120],"NA","This trial studies how well spectroscopic magnetic resonance imaging (MRI) guided proton therapy works in assessing metabolic change in pediatric patients with brain tumors. The non-invasive imaging, such as spectroscopic MRI may help to map the differences in tumor metabolism compared to healthy tissue without injection of any contrast agent.",[123],"Malignant Brain Glioma","2026-03-02",{"date":126,"type":127},"2026-03-04","ACTUAL",{"date":129,"type":127},"2018-12-20",{"date":131,"type":117},"2030-10-13",{"name":5,"class":6},3]